CUTISS vs Genentech
Side-by-side comparison of AI visibility scores, market position, and capabilities
CUTISS is a Swiss biotech developing personalized dermo-epidermal skin grafts from patient cells for large skin defect treatment; denovoSkin product reduces reliance on painful autografts; raised CHF 30M+ in funding;
About
CUTISS is a Swiss clinical-stage biotechnology company founded in 2017 as a spin-off from the University Children's Hospital Zurich, focused on developing personalized bioengineered skin grafts for patients with large skin defects caused by severe burns, rare congenital skin diseases, and traumatic wounds. The company's lead product, denovoSkin, is a dermo-epidermal skin graft manufactured by combining a small biopsy of a patient's own skin cells with a proprietary hydrogel scaffold — which is then cultured to grow a full-thickness skin equivalent containing both the dermis (dermal layer) and epidermis (outer layer). Because the graft uses the patient's own cells, it avoids immune rejection without the need for immunosuppression.
Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avastin, Rituxan, and Tecentriq.
About
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching the modern biotechnology industry. Acquired by Roche in 2009 for $46.8 billion, Genentech continues to operate with significant R&D autonomy as the US hub for Roche's pharmaceutical innovation.\n\nThe company is best known for pioneering cancer biologics, developing Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for multiple cancers, Rituxan (rituximab) for lymphoma, and Tecentriq (atezolizumab) for PD-L1 immunotherapy. Its discovery engine spans oncology, neuroscience, ophthalmology, and immunology with a robust early-stage pipeline leveraging AI-assisted target identification.\n\nGenentech generates tens of billions in annual revenue through Roche's Pharmaceuticals Division and remains one of the most productive biotech research sites in the world, consistently ranked among top employers in life sciences. The South San Francisco campus employs over 13,000 scientists, clinicians, and engineers, anchoring the Bay Area as a global biotech hub.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.